Publications

Journal Article Ppublish 389 citations
Electronic publication date
March 1, 2010

View on Pubmed.gov 22263017 View on doi.org

Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update.

Search for publications in this journal J Thorac Dis - 2(1):48-51

Abstract

Epidermal growth factor receptor is a trans-membrane glycoprotein with an extracellular epidermal growth factor binding domain and an intracellular tyrosine kinase domain that regulates signaling pathways to control cellular proliferation. Epidermal growth factor receptor binding to its ligand results in autophosphorylation by intrinsic tyrosine/kinase activity, triggering several signal transduction cascades. Constitutive or sustained activation of these sequences of downstream targets is thought to yield more aggressive tumor phenotypes. Mutations in epidermal growth factor receptor have been discovered in association with some lung cancers. Lung adenocarcinomas with mutated epidermal growth factor receptor have significant responses to tyrosine kinase inhibitors, although for unselected patients it does not appear to have a survival benefit. However, in a subset of patients (non-smoking Asian women with adenocarcinoma, particularly with a bronchioloalveolar carcinoma), there appears to be a significant survival advantage. Both EGFR mutation and gene amplification status may be important in determining which tumors will respond to tyrosine kinase inhibitors.

References

Clin Cancer Res. 2006 Jul 1;12(13):3908-14

Clin Cancer Res. 2006 Nov 1;12(21):6494-501

J Natl Cancer Inst. 2005 May 4;97(9):643-55

J Cancer Res Clin Oncol. 2008 May;134(5):569-77

Cited by 389 citations (total)

Journal Article

Familial risk for lung cancer.

Electronic publication date March 31, 2017

Search for publications in this journal Oncol Lett

Madiha Kanwal [...] Yi Cao et al.

Lung cancer, which has a low survival rate, is a leading cause of cancer-associated mortality worldwide. Smoking and air pollution...

Journal Article

Silibinin Regulates Tumor Progression and Tumorsphere Formation by Suppressing PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Cells.

Electronic publication date July 3, 2021

Search for publications in this journal Cells

Alexis Rugamba [...] Kyoung-Jin Jang et al.

Recently, natural compounds have been used globally for cancer treatment studies. Silibinin is a natural compound extracted from (milk...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties